tradingkey.logo
tradingkey.logo
Buscar

Eton Pharmaceuticals Inc

ETON
Añadir a la lista de seguimiento
37.500USD
+0.870+2.38%
Cierre 07/02, 13:00ETCotizaciones retrasadas 15 min
1.03BCap. mercado
PérdidaP/E TTM

Más Datos de Eton Pharmaceuticals Inc Compañía

Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.

Información de Eton Pharmaceuticals Inc

Símbolo de cotizaciónETON
Nombre de la empresaEton Pharmaceuticals Inc
Fecha de salida a bolsaNov 09, 2018
Director ejecutivoBrynjelsen (Sean E)
Número de empleados31
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 09
Dirección21925 W Field Pkwy Ste 235
CiudadDEER PARK
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal60010-7278
Teléfono18477877361
Sitio Webhttps://etonpharma.com/
Símbolo de cotizaciónETON
Fecha de salida a bolsaNov 09, 2018
Director ejecutivoBrynjelsen (Sean E)

Ejecutivos de Eton Pharmaceuticals Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Sean E. Brynjelsen
Mr. Sean E. Brynjelsen
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
828.68K
-14.48%
Dr. Norbert G. Riedel, Ph.D.
Dr. Norbert G. Riedel, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
169.56K
+32.33%
Mr. Charles J. (Chuck) Casamento
Mr. Charles J. (Chuck) Casamento
Independent Director
Independent Director
93.42K
--
Mr. Paul V. Maier
Mr. Paul V. Maier
Independent Director
Independent Director
84.75K
--
Mr. James R. Gruber
Mr. James R. Gruber
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
15.96K
-36.06%
Ms. Ipek Erdogan-Trinkaus
Ms. Ipek Erdogan-Trinkaus
Chief Commercial Officer
Chief Commercial Officer
289.00
--
Ms. Jennifer (Jenn) Adams
Ms. Jennifer (Jenn) Adams
Independent Director
Independent Director
--
--
Mr. David C. Krempa
Mr. David C. Krempa
Chief Business Officer
Chief Business Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Sean E. Brynjelsen
Mr. Sean E. Brynjelsen
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
828.68K
-14.48%
Dr. Norbert G. Riedel, Ph.D.
Dr. Norbert G. Riedel, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
169.56K
+32.33%
Mr. Charles J. (Chuck) Casamento
Mr. Charles J. (Chuck) Casamento
Independent Director
Independent Director
93.42K
--
Mr. Paul V. Maier
Mr. Paul V. Maier
Independent Director
Independent Director
84.75K
--
Mr. James R. Gruber
Mr. James R. Gruber
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
15.96K
-36.06%
Ms. Ipek Erdogan-Trinkaus
Ms. Ipek Erdogan-Trinkaus
Chief Commercial Officer
Chief Commercial Officer
289.00
--

Preguntas frecuentes

¿Quiénes son los cinco principales accionistas de Eton Pharmaceuticals Inc?

Los cinco principales accionistas de Eton Pharmaceuticals Inc son: Mr. Sean E. Brynjelsen

¿Cuántas instituciones poseen acciones de Eton Pharmaceuticals Inc (ETON)?

A fecha de 2026Q1, 235 instituciones poseen acciones de Eton Pharmaceuticals Inc, con un valor de mercado combinado de aproximadamente 15.99M, lo que representa el 58.43% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -3678435.00.